Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, AL 35294, U.S.A.
Biochem J. 2010 May 13;428(2):255-67. doi: 10.1042/BJ20100090.
Abnormal smooth muscle cell proliferation is a hallmark of vascular disease. Although growth factors are known to contribute to cell hyperplasia, the changes in metabolism associated with this response, particularly mitochondrial respiration, remain unclear. Given the increased energy requirements for proliferation, we hypothesized that PDGF (platelet-derived growth factor) would stimulate glycolysis and mitochondrial respiration and that this elevated bioenergetic capacity is required for smooth muscle cell hyperplasia. To test this hypothesis, cell proliferation, glycolytic flux and mitochondrial oxygen consumption were measured after treatment of primary rat aortic VSMCs (vascular smooth muscle cells) with PDGF. PDGF increased basal and maximal rates of glycolytic flux and mitochondrial oxygen consumption; enhancement of these bioenergetic pathways led to a substantial increase in the mitochondrial reserve capacity. Interventions with the PI3K (phosphoinositide 3-kinase) inhibitor LY-294002 or the glycolysis inhibitor 2-deoxy-D-glucose abrogated PDGF-stimulated proliferation and prevented augmentation of glycolysis and mitochondrial reserve capacity. Similarly, when L-glucose was substituted for D-glucose, PDGF-dependent proliferation was abolished, as were changes in glycolysis and mitochondrial respiration. Interestingly, LDH (lactate dehydrogenase) protein levels and activity were significantly increased after PDGF treatment. Moreover, substitution of L-lactate for D-glucose was sufficient to increase mitochondrial reserve capacity and cell proliferation after treatment with PDGF; these effects were inhibited by the LDH inhibitor oxamate. These results suggest that glycolysis, by providing substrates that enhance the mitochondrial reserve capacity, plays an essential role in PDGF-induced cell proliferation, underscoring the integrated metabolic response required for proliferation of VSMCs in the diseased vasculature.
平滑肌细胞异常增殖是血管疾病的一个标志。虽然已知生长因子有助于细胞增生,但与这种反应相关的代谢变化,特别是线粒体呼吸,仍不清楚。鉴于增殖需要增加能量需求,我们假设 PDGF(血小板衍生生长因子)会刺激糖酵解和线粒体呼吸,并且这种升高的生物能量能力是平滑肌细胞增生所必需的。为了验证这一假设,在用 PDGF 处理原代大鼠主动脉 VSMCs(血管平滑肌细胞)后,测量了细胞增殖、糖酵解通量和线粒体耗氧量。PDGF 增加了基础和最大糖酵解通量和线粒体耗氧量;这些生物能量途径的增强导致线粒体储备能力的大幅增加。用 PI3K(磷酸肌醇 3-激酶)抑制剂 LY-294002 或糖酵解抑制剂 2-脱氧-D-葡萄糖进行干预,可阻断 PDGF 刺激的增殖,并防止糖酵解和线粒体储备能力的增强。同样,当用 L-葡萄糖替代 D-葡萄糖时,PDGF 依赖性增殖被废除,糖酵解和线粒体呼吸的变化也被废除。有趣的是,PDGF 处理后 LDH(乳酸脱氢酶)蛋白水平和活性显著增加。此外,在用 PDGF 处理后,用 L-乳酸替代 D-葡萄糖足以增加线粒体储备能力和细胞增殖;这些作用被 LDH 抑制剂 oxamate 抑制。这些结果表明,糖酵解通过提供增强线粒体储备能力的底物,在 PDGF 诱导的细胞增殖中发挥重要作用,强调了在患病血管中 VSMCs 增殖所需的综合代谢反应。